BLOOD CELL TECHNOLOGIES LLC
Stony Brook, NY · Biotech · Private
Small molecule inhibitors of BLVRB (biliverdin reductase) for selective targeting of cancer cell antioxidant pathways
- Grants
- $4.2M
- 11 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 1
- 0 granted · 1 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Development of a biliverdin IX Beta reductase redox inhibitor for enhanced platelet production | $220,991 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a biliverdin IX Beta reductase redox inhibitor for enhanced platelet production | $220,991 | |
| Federal grant | Department of Health and Human Services · Phase I · HLS-Detection of RNA biomarkers in individual platelets | $243,104 | |
| Federal grant | Department of Health and Human Services · Phase I · HLS Detection of RNA biomarkers in individual platelets | $243,104 | |
| Federal grant | Department of Health and Human Services · Phase I · Detection of fetal platelets in maternal blood using platelet RNA biomarkers. | $272,302 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimization of biliverdin IXβ reductase redox inhibitors as novel reagents for enhancing platelet production | $690,965 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimization of biliverdin IXβ reductase redox inhibitors as novel reagents for enhancing platelet production | $763,993 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimization of biliverdin IXβ reductase redox inhibitors as novel reagents for enhancing platelet production | $613,208 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Development of a new class of BLVRB-targeted redox therapeutics in breast cancer | $285,200 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Development of a new class of BLVRB-targeted redox therapeutics in breast cancer | $285,200 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Second Generation BLVRB Inhibitors for Treating Chemotherapy Induced Thrombocytopenia | $400,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3150 | VIBE PHARMACEUTICALS LLC | — | — |
| 3151 | SYNBAL INC | — | — |
| 3152 | ANANEO THERAPEUTICS INC | — | — |
| 3153 | BLOOD CELL TECHNOLOGIES LLC | — | — |
| 3154 | PETAOMICS, INC. | — | — |
| 3155 | OSEL, INC. | — | — |
| 3156 | SERPLUS TECHNOLOGY, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Inhibitors Of Biliverdin Reductase B (blvrb)application
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.